MedTrace Logo

International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi

NCT03072030 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2020-08-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate immunogenicity, epidemiological efficacy and safety of medicinal product GamEvac-Combi - Combined Vector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose

Conditions

  • Ebola Virus Disease
  • Prevention

Interventions

BIOLOGICAL

GamEvac-Combi (vaccine)

vaccination

BIOLOGICAL

Placebo

vaccination

Sponsors & Collaborators

  • CREMS (Centre de Recherche Epidémiologie, Microbiologie et Soins médicaux )

    collaborator UNKNOWN

  • Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

    lead OTHER

Principal Investigators

  • Sylla Ali Lathyr · physician administrator

  • Marina Rusanova, MD, PhD · doctor of infectious department

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-03
Primary Completion
2019-12-31
Completion
2020-07-31

Countries

  • Guinea
  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03072030 on ClinicalTrials.gov